We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Cost-effectiveness of FDG-PET

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 21, 2011
Last Update Posted: September 21, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Netherlands: Ministry of Health, Welfare and Sports
Information provided by (Responsible Party):
Juliano Julio Cerci, University of Sao Paulo
Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Oncologic Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Further study details as provided by Juliano Julio Cerci, University of Sao Paulo:

Enrollment: 500
Study Start Date: June 2005
Study Completion Date: September 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
oncologic patients
initial staging

Detailed Description:
To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
500 oncologic patients

Inclusion Criteria:

  • Cancer

Exclusion Criteria:

  • Other malignancy
  • Uncontrolled Diabetes
  • Pregnancy
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Juliano Julio Cerci, Pesquisador executante, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT01438164     History of Changes
Other Study ID Numbers: USP0460/05
First Submitted: September 20, 2011
First Posted: September 21, 2011
Last Update Posted: September 21, 2011
Last Verified: September 2011

Keywords provided by Juliano Julio Cerci, University of Sao Paulo:
Evaluate the cost impact in the evaluation of oncologic patients.

To Top